Arany Soosainathan
YOU?
Author Swipe
View article: Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitors impair cell viability in 2D and 3D culture. A and B, A total of 4,000 to 8,000 cells were seeded in 96-well tissue culture plates and treated at day 1 and 3 with the CDK9 inhibitors NVP-2 (A) or AZD4573…
View article: Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S1
View article: Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet many patients relapse with therapy-resistant dis…
View article: Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Methods
View article: Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S4
View article: Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S2
View article: Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Two-dimensional kinase inhibitor screens in LTED breast cancer cell line models. A, Schematic representation of the study. B, 2D screens at 1 μmol/L final drug concentration (see Materials and Methods). Sigma plots represent …
View article: Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S5
View article: Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S4
View article: Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Two-dimensional kinase inhibitor screens in LTED breast cancer cell line models. A, Schematic representation of the study. B, 2D screens at 1 μmol/L final drug concentration (see Materials and Methods). Sigma plots represent …
View article: Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitors impair cell viability in 2D and 3D culture. A and B, A total of 4,000 to 8,000 cells were seeded in 96-well tissue culture plates and treated at day 1 and 3 with the CDK9 inhibitors NVP-2 (A) or AZD4573…
View article: Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitor AZD4573 drives tumor regression in endocrine therapy and palbociclib-resistant PDXs. A, 2–5 × 104 dissociated PDO cells were seeded per well in 96-well tissue culture plates in 10% Matrigel. The resulting o…
View article: Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Tables S1, S2, S3, S4, S5a, S5b, S5c, S5d, S6
View article: Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S1
View article: Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Tables S1, S2, S3, S4, S5a, S5b, S5c, S5d, S6
View article: Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitor AZD4573 drives tumor regression in endocrine therapy and palbociclib-resistant PDXs. A, 2–5 × 104 dissociated PDO cells were seeded per well in 96-well tissue culture plates in 10% Matrigel. The resulting o…
View article: Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Three-dimensional kinase inhibitor screens in LTED and palbociclib-resistant breast cancer cell line models. Three-dimensional assays were performed at 250 nmol/L final drug concentration (see Materials and Methods). Compounds with a robus…
View article: Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Three-dimensional kinase inhibitor screens in LTED and palbociclib-resistant breast cancer cell line models. Three-dimensional assays were performed at 250 nmol/L final drug concentration (see Materials and Methods). Compounds with a robus…
View article: Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S2
View article: Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S3
View article: Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet many patients relapse with therapy-resistant dis…
View article: Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S5
View article: Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Methods
View article: Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S3
View article: Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers Open
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet many patients relapse with therapy-resistant disease. Deter…
View article: Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series
Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series Open
Introduction of the IOFS analysis during intrafascial nerve spare RRP has reduced PSM and the rate of urinary incontinence.